Difference between revisions of "Catenacci DV, et al. J. Clin. Oncol. (2015) cited as Ref 607 in DOI: 10.1038/s41392-020-0110-5 (Q9870)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 33, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib a hedgehog pathway inhibitor in patients with metastatic pancreatic cancer, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib a hedgehog pathway inhibitor in patients with metastatic pancreatic cancer (English) | ||
| Property / title: Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib a hedgehog pathway inhibitor in patients with metastatic pancreatic cancer (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:05, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Catenacci DV, et al. J. Clin. Oncol. (2015) cited as Ref 607 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Catenacci DV
0 references
2015
0 references
J. Clin. Oncol.
0 references
33
0 references
Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib a hedgehog pathway inhibitor in patients with metastatic pancreatic cancer (English)
0 references
